In another work, an ADC based on a novel topoisomerase I inhibitor conjugated with an anti-HER2 antibody using a peptide linker was developed to treat trastuzumab-emtansine (T-DM1)-insensitive, high HER2-positive breast cancers [112]. The gene discussed is ERBB2; the disease is breast cancer.